Luke J. Laffin

4 days ago | healio.com | Erik Swain |Matthew Weir |Luke J. Laffin

• Topline data show lorundrostat lowers systolic blood pressure in patients with hypertension and chronic kidney disease. • The drug also showed expected reductions in urine albumin-to-creatinine ratio and eGFR. Mineralys Therapeutics announced positive topline results from its phase 2 Explore-CKD trial, in which lorundrostat lowered blood pressure in patients with hypertension and chronic kidney disease.

2 months ago | healio.com | Regina Schaffer |Katie Kalvaitis |Keith C. Ferdinand |Luke J. Laffin

Novel agent targeting aldosterone lowers blood pressure for adults with resistant hypertension• A dose-escalation strategy did not result in greater BP lowering. CHICAGO — The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well-treated, uncontrolled and “true” treatment-resistant hypertension, according to data from a new phase 2b study.

Nov 18, 2024 | healio.com | Regina Schaffer |Richard Smith |Luke J. Laffin |Stephen Nicholls

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: An investigational oral drug lowered lipoprotein(a) levels by more than 80% at the highest dose for adults at high CV risk. There were no new safety concerns in the phase 2 study.

Jul 29, 2024 | healio.com | Regina Schaffer |Erik Swain |Michael Hall |Luke J. Laffin

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Obesity drugs induce substantial weight loss and may reduce blood pressure but are priced out of reach for many Americans. Some patients with obesity may require combination therapy with drugs and surgery.

Jul 26, 2024 | healio.com | Regina Schaffer |Erik Swain |Michael Hall |Luke J. Laffin

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Data demonstrate a sustained reduction in BP after bariatric surgery for people with obesity and uncontrolled hypertension. Emerging data suggest similar results for people prescribed obesity medications.